SenseSplice: The AI-powered biotech startup transforming Berlin labs this month

Berlin-based biotech startup SenseSplice has launched an AI-powered gene editing platform that promises to accelerate biomedical research and reduce costs for labs across Europe. The company, headquartered in the Mitte district's Factory Berlin innovation hub, unveiled its beta platform this week, offering real-time optimization for CRISPR gene editing experiments.

This breakthrough arrives as demand surges for advanced biotechnologies capable of addressing urgent global health challenges, including drug-resistant infections and rare genetic diseases. With European Union funding now boosting biotech ventures focused on precision medicine, SenseSplice's launch is well-timed to capitalize on this momentum.

Local innovation anchors in Berlin’s vibrant biotech scene

SenseSplice’s growth is deeply rooted in Berlin’s thriving tech landscape, particularly through partnerships with renowned institutions like the Berlin Institute of Health (BIH) and the Max Delbrück Center for Molecular Medicine in Buch. These collaborations provide access to cutting-edge research samples and clinical data sets that inform SenseSplice’s AI algorithms.

Additionally, the startup benefits from support via the Berlin Startup Stipendium program, which offers both funding and workspace in the TechQuartier Berlin complex near Alexanderplatz. This ecosystem of research labs, investors, and entrepreneurs has helped SenseSplice scale its technology swiftly since its founding in late 2024.

Promising data signals shift in biotech research economics

According to SenseSplice’s internal reports, their AI-driven editing platform reduces trial and error cycles by up to 40%, potentially saving laboratories €150,000 annually in consumables and labor costs. Early users include Charité, Universitätsmedizin Berlin, which began piloting the system this March to speed up gene therapy candidate development.

Price-wise, SenseSplice has introduced subscription tiers ranging from €3,500 to €12,000 per year, depending on usage volume-noticeably more affordable than legacy platforms that charge per experiment. With over 25 labs currently signed up during the beta phase, they aim to reach 100 paying customers across Germany and neighboring countries by the end of 2026.

By harnessing AI’s ability to predict gene-editing outcomes, SenseSplice could reshape experimentation precision, reduce redundant work, and ultimately accelerate treatments for complex conditions.

For Berlin-based researchers interested in exploring SenseSplice’s platform, demos can be booked through the Factory Berlin event space on Schlesische Straße. Startups and academic teams can also apply for trial access via the Berlin Innovation Fund’s biotech initiative launched earlier this year. With growing interest from pharmaceutical companies eyeing efficient drug discovery, SenseSplice’s next steps include expanding its AI to editable RNA targets and scaling partnerships throughout Europe.